SecBot SecBot
SECBOTREPLAY Home › Report › QTTB

QTTB · Q32 Bio reported positive 36-week topline results from Part B of the…

Q32 Bio Inc. · 8-K filed Jul 13, 2026 at 07:09 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 13, 2026 at 07:09 ET

Q32 Bio reported positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata, showing a 35.3% mean reduction in SALT score and 40% SALT-20 response in the mITT population with a favorable safety profile. The company also disclosed it paid off the remaining ~$6.8M loan from Silicon Valley Bank, eliminating debt. The data supports advancement to a registration-directed program in H1 2027, a significant milestone for this clinical-stage biotech.

  • Mean SALT score reduction of 35.3% in mITT population at Week 36
  • 40.0% (10/25) of mITT patients achieved SALT-20 (80% scalp hair coverage) at Week 36
  • 30.3% (10/33) of ITT patients achieved SALT-20
  • 44.0% (11/25) mITT achieved both SALT30 and SALT50 responses

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access